SLU-PP-332
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
SLU-PP-332 is a small-molecule pan-ERR (estrogen-related receptor) agonist — the second-generation “exercise pill” research compound, developed in academic metabolic-pharmacology labs (the SLU-PP series). Like AICAR, it’s not a peptide but is grouped with the metabolic cluster. thepeptidelist.com files it under weight-loss (secondary: performance). (Note: the compound is sometimes written SLU-PP-322; the canonical designation in the source studies is SLU-PP-332.)
SLU-PP-332 sits in the exercise-mimetic sub-story alongside AICAR — both are small molecules chasing the same “endurance-training-in-a-vial” goal through different pathways: AICAR through AMPK, SLU-PP-332 through pan-ERR agonism.
What does it do in my body?
Per thepeptidelist.com: an ERR (estrogen-related receptor) agonist that may activate exercise-like metabolic pathways and improve endurance.
The estrogen-related receptors (ERRα/β/γ) are master regulators of mitochondrial biogenesis and oxidative metabolism — the same program endurance training switches on. SLU-PP-332 activates them directly, which is why it’s pitched as an exercise mimetic distinct from the AMPK route AICAR takes.
What ERRs actually are. Despite the name, estrogen-related receptors are not involved in estrogen signaling and do not affect estrogen levels in either sex. They are orphan nuclear receptors — structurally similar to estrogen receptors but with no known endogenous ligand regulating them the classical hormone way. They are master energy-metabolism regulators, highly expressed in tissues with high oxidative demand: skeletal muscle, cardiac muscle, brown adipose tissue, brain. Activation turns on genes governing: mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation. This is the same gene program aerobic exercise activates — hence the exercise-mimetic classification. [ESTABLISHED — receptor biology]
SLU-PP-332 activates all three ERR isoforms (pan-agonist) with highest potency at ERR-α, which the preclinical research identifies as the primary driver of the aerobic exercise adaptive response. ERR-α dependency was confirmed in the ACS Chemical Biology study by blocking the receptor and observing loss of the endurance improvement.
The critical distinction from all conventional fat-loss compounds. Every major fat-loss compound in common use — caffeine, yohimbine, ephedrine, most thermogenics — operates by elevating catecholamines via the sympathetic nervous system. The calorie burn comes from elevated heart rate, jitteriness, sleep disruption, and adrenal stress. SLU-PP-332 does not touch the sympathetic nervous system. It operates at the level of gene transcription — instructing cells to behave as if performing endurance training. In the rodent data: no heart rate increase, no appetite change, no nervous system stimulation, no adrenal loading. This makes it mechanistically unlike any existing fat-loss intervention.
How can it help me?
- Where the science stands: 3 preclinical studies cited (mouse exercise-mimetic + aging-kidney model); 0 human trials
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No human safety data exists. In rodent studies:
- No reported liver toxicity
- No reported kidney toxicity
- No reported cardiac toxicity
- No effect on heart rate or the sympathetic nervous system
- No hormone pathway involvement — no suppression of endogenous hormone production reported; mechanism operates via nuclear receptor gene transcription, not HPG axis ``
Cycling: Based on the mechanism (no HPG axis involvement) and the absence of reported hormone suppression in preclinical data, no cycling protocol is indicated — but this conclusion rests on animal and in-vitro data only. Human hormone markers have not been formally tested.
Doping flag: Anti-doping detection methods are already in development for SLU-PP-332 and the related SLU-PP-915 (Möller, Krug, Thevis, PMID 41588687). The research community already classifies this compound as having real performance-enhancement and doping potential — worth knowing for competitive athletes operating under WADA or similar frameworks.
Regulatory status: research_only, not FDA-approved, not eligible for compounding. Anti-doping detection methods already in development (doping-potential flag). OHM grade: D / provisional (encyclopedia-only). Not in Alyve’s launch catalog of 15 SKUs.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
Reconstitution — DMSO required, not water
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
No human dosing protocol exists — entirely preclinical.
SLU-PP-332 is a hydrophobic small molecule and does not dissolve in bacteriostatic water or saline. Attempting to reconstitute it in water produces a cloudy, separated mixture with visible settling — the compound never enters proper solution. The correct solvent is DMSO, in which solubility is approximately 75 mg/ml.
Step-by-step protocol:
- Add SLU-PP-332 powder to DMSO and swirl gently to dissolve — do not vortex or shake vigorously
- Allow a few minutes; solution should become clear with essentially no particulate
- If a diluted aqueous working concentration is needed (e.g. for a cell assay), add sterile bacteriostatic water or PBS slowly, in small increments, to avoid precipitation
- Keep the final DMSO concentration at or below ~1% for sensitive assays
DMSO handling cautions:
- DMSO is a penetration enhancer — it carries dissolved compounds across skin and biological membranes. A contaminated or low-purity SLU-PP-332 stock is a more significant concern with DMSO than with a water carrier for this reason. Use only verified-purity material.
- Local skin effects (redness, stinging, itching, transient swelling) are possible on contact; dose- and concentration-dependent
- The oxidative stress sometimes attributed to DMSO is primarily a secondary effect of tissue irritation, not DMSO acting as a direct pro-oxidant
Note on tablet vs. lyophilized powder: Commercial SLU-PP-332 is sometimes sold as tablets or capsules, which contain binders and fillers in addition to the active compound. These excipients may independently contribute to cloudiness when the tablet is added to water, separate from the compound’s own poor water solubility. Lyophilized (powder) form in DMSO is the cleaner preparation for research use.
Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. Your exact units depend on your own vial's mg and how much bacteriostatic water you added — use the same concentration you mixed above.
What should I avoid combining — and what's synergistic?
Source: Pruski, Research Radar (Substack), 2026-07-21 — n=1 bench experiment; consistent with SLU-PP-332’s known hydrophobic chemical profile. See.
How can I buy this?
We don't have a verified affiliate source for SLU-PP-332 yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
The best-documented “exercise in a pill” compound in this evidence family — a pan-ERR agonist with genuine mouse exercise-mimetic and anti-aging kidney data. Still entirely preclinical, and anti-doping science is already building detection methods for it.
| Class | Small-molecule pan-ERR (estrogen-related receptor) agonist — second-generation “exercise pill” research compound (not a true peptide) |
| Mechanism (one line) | Activates ERRα/β/γ, master regulators of mitochondrial biogenesis and oxidative metabolism, turning on exercise-like metabolic pathways |
| Evidence base | 3 preclinical studies cited (mouse exercise-mimetic + aging-kidney model); 0 human trials |
| Safety record | No human safety data; anti-doping detection methods already in development, signaling recognized doping potential |
| Regulatory status | research_only; not FDA-approved; not eligible for compounding |
What it is
SLU-PP-332 is a small-molecule pan-ERR (estrogen-related receptor) agonist — the second-generation “exercise pill” research compound, developed in academic metabolic-pharmacology labs (the SLU-PP series). Like AICAR, it’s not a peptide but is grouped with the metabolic cluster. thepeptidelist.com files it under weight-loss (secondary: performance). (Note: the compound is sometimes written SLU-PP-322; the canonical designation in the source studies is SLU-PP-332.)
SLU-PP-332 sits in the exercise-mimetic sub-story alongside AICAR — both are small molecules chasing the same “endurance-training-in-a-vial” goal through different pathways: AICAR through AMPK, SLU-PP-332 through pan-ERR agonism.
How it works
Per thepeptidelist.com: an ERR (estrogen-related receptor) agonist that may activate exercise-like metabolic pathways and improve endurance.
The estrogen-related receptors (ERRα/β/γ) are master regulators of mitochondrial biogenesis and oxidative metabolism — the same program endurance training switches on. SLU-PP-332 activates them directly, which is why it’s pitched as an exercise mimetic distinct from the AMPK route AICAR takes.
What ERRs actually are. Despite the name, estrogen-related receptors are not involved in estrogen signaling and do not affect estrogen levels in either sex. They are orphan nuclear receptors — structurally similar to estrogen receptors but with no known endogenous ligand regulating them the classical hormone way. They are master energy-metabolism regulators, highly expressed in tissues with high oxidative demand: skeletal muscle, cardiac muscle, brown adipose tissue, brain. Activation turns on genes governing: mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation. This is the same gene program aerobic exercise activates — hence the exercise-mimetic classification. [ESTABLISHED — receptor biology]
SLU-PP-332 activates all three ERR isoforms (pan-agonist) with highest potency at ERR-α, which the preclinical research identifies as the primary driver of the aerobic exercise adaptive response. ERR-α dependency was confirmed in the ACS Chemical Biology study by blocking the receptor and observing loss of the endurance improvement.
The critical distinction from all conventional fat-loss compounds. Every major fat-loss compound in common use — caffeine, yohimbine, ephedrine, most thermogenics — operates by elevating catecholamines via the sympathetic nervous system. The calorie burn comes from elevated heart rate, jitteriness, sleep disruption, and adrenal stress. SLU-PP-332 does not touch the sympathetic nervous system. It operates at the level of gene transcription — instructing cells to behave as if performing endurance training. In the rodent data: no heart rate increase, no appetite change, no nervous system stimulation, no adrenal loading. This makes it mechanistically unlike any existing fat-loss intervention.
What the research shows
This is the best-documented exercise-mimetic in this compound cluster, but still entirely preclinical — 0 human trials published.
Burris lab — two landmark rodent studies
Thomas Burris at the University of Florida’s College of Pharmacy led the development of SLU-PP-332 and published the two core efficacy studies.
Study 1 — Journal of Pharmacology and Experimental Therapeutics (fat loss and metabolic syndrome model)
Diet-induced obese mice and genetically obese mice received SLU-PP-332 twice daily for 28 days on a high-fat, high-calorie diet — researchers intentionally kept the diet unchanged, testing metabolic change in the absence of dietary or exercise intervention.
Key results:
- Drug-treated mice weighed 12% less than controls after 28 days
- 10× less fat accumulation in treated vs. untreated mice on the same high-fat diet
- Food intake: unchanged — the compound did not reduce appetite
- Exercise: not increased
- Heart rate: no effect
- Sympathetic nervous system: no effect
- Respiratory exchange ratio (RER): shifted toward fat oxidation — whole-body metabolism switched to preferentially burning fat as fuel substrate
- Obese mouse metabolic markers: improved glucose tolerance and insulin sensitivity
- Liver: reduced hepatic fat accumulation on a high-fat diet (reduced early fatty liver signal)
Study 2 — ACS Chemical Biology (exercise-mimetic foundational paper)
Established SLU-PP-332 as a true exercise mimetic at the molecular level by examining what happens inside muscle after treatment.
Key results:
- Mitochondrial function: increased mitochondrial function and cellular respiration — muscle cells producing more energy more efficiently
- Muscle fiber type shift: increased type 2A (fast-twitch oxidative) muscle fibers. These fibers are fatigue-resistant and metabolically active — the muscle physically remodeled toward a phenotype better adapted for fat-fueled endurance performance, without any training stimulus.
- PGC-1α upregulation: increased expression of PGC-1α, the master regulator of mitochondrial biogenesis — the same protein exercise upregulates
- GLUT4 upregulation: increased expression of GLUT4, the primary glucose transporter in skeletal muscle, improving glucose handling in the muscle itself — a standard exercise adaptation produced pharmacologically
- Exercise endurance: treated mice ran farther and longer than controls
- ERR-α dependency confirmed: blocking ERR-α abolished the endurance enhancement — the specific receptor was confirmed as the causal driver
Significance of the type 2A fiber shift: Type 2A fibers carry higher baseline energy expenditure than the fiber types they partially replace. Their greater proportion means improved fat oxidation even at rest or low activity, and a higher ceiling for aerobic performance during actual exercise. The compound produced structural muscle adaptation without the training that normally produces it.
Other supporting studies
- Wang et al., Am J Pathol 2023 (PMID 37717940) — ERR agonism reversed age-related kidney dysfunction, albuminuria, and inflammation in aging mice over an 8-week course. An anti-aging / organ-protection angle beyond fat loss.
- Möller, Krug, Thevis, Rapid Commun Mass Spectrom 2026 (PMID 41588687) — characterized metabolites of SLU-PP-332 and SLU-PP-915 as “Novel Pan-ERR Agonists With Doping Potential” — anti-doping science is already building detection methods. Same trajectory AICAR followed.
- Billon et al., J Pharmacol Exp Ther 2026 (PMID 41421047) — an orally active ERR agonist (the related SLU-PP-915) enhanced aerobic exercise capacity in mice. Confirm whether this paper also covers SLU-PP-332 directly.
The honest read: early but genuinely interesting. Two rodent studies from a credible academic lab show fat-loss + endurance-mimetic effects with a clean sympathetic-nervous-system profile. No human trials exist. Surface as a compound to watch, not a current protocol. Heavy posture on the JPET and ACS Chem Biol PMIDs — both need independent confirmation before citing numbers customer-facing.
Exercise synergy — additive, not redundant
A natural question for users who already exercise: does SLU-PP-332 just duplicate exercise’s signal, making it redundant? The mechanistic picture says no.
SLU-PP-332 drives PGC-1α via ERR-α activation (gene transcription). Exercise drives PGC-1α via AMPK + calcium signaling (two different upstream triggers). These are distinct upstream inputs into the same downstream adaptive protein — combining them increases total signaling without overlap. More PGC-1α signal → more mitochondrial biogenesis → better metabolic adaptation.
The MOTS-c literature provides a useful parallel: MOTS-c (another exercise-mimetic compound) showed significantly better outcomes in mice that were eating well and exercising versus sedentary + poor diet animals — the compound amplified healthy behaviors rather than substituting for them.
Positive feedback loop: more mitochondrial mass (built by SLU-PP-332) → more ERR activity → greater responsiveness to both the compound and subsequent exercise — the adaptive ceiling rises with use.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These compounds are sold for research use only and are not FDA-approved drugs. This is not medical advice.
No human dosing protocol exists — entirely preclinical.
Reconstitution — DMSO required, not water
SLU-PP-332 is a hydrophobic small molecule and does not dissolve in bacteriostatic water or saline. Attempting to reconstitute it in water produces a cloudy, separated mixture with visible settling — the compound never enters proper solution. The correct solvent is DMSO, in which solubility is approximately 75 mg/ml.
Step-by-step protocol:
- Add SLU-PP-332 powder to DMSO and swirl gently to dissolve — do not vortex or shake vigorously
- Allow a few minutes; solution should become clear with essentially no particulate
- If a diluted aqueous working concentration is needed (e.g. for a cell assay), add sterile bacteriostatic water or PBS slowly, in small increments, to avoid precipitation
- Keep the final DMSO concentration at or below ~1% for sensitive assays
DMSO handling cautions:
- DMSO is a penetration enhancer — it carries dissolved compounds across skin and biological membranes. A contaminated or low-purity SLU-PP-332 stock is a more significant concern with DMSO than with a water carrier for this reason. Use only verified-purity material.
- Local skin effects (redness, stinging, itching, transient swelling) are possible on contact; dose- and concentration-dependent
- The oxidative stress sometimes attributed to DMSO is primarily a secondary effect of tissue irritation, not DMSO acting as a direct pro-oxidant
Source: Pruski, Research Radar (Substack), 2026-07-21 — n=1 bench experiment; consistent with SLU-PP-332’s known hydrophobic chemical profile. See.
Note on tablet vs. lyophilized powder: Commercial SLU-PP-332 is sometimes sold as tablets or capsules, which contain binders and fillers in addition to the active compound. These excipients may independently contribute to cloudiness when the tablet is added to water, separate from the compound’s own poor water solubility. Lyophilized (powder) form in DMSO is the cleaner preparation for research use.
Side effects & management
No human safety data exists. In rodent studies:
- No reported liver toxicity
- No reported kidney toxicity
- No reported cardiac toxicity
- No effect on heart rate or the sympathetic nervous system
- No hormone pathway involvement — no suppression of endogenous hormone production reported; mechanism operates via nuclear receptor gene transcription, not HPG axis ``
Cycling: Based on the mechanism (no HPG axis involvement) and the absence of reported hormone suppression in preclinical data, no cycling protocol is indicated — but this conclusion rests on animal and in-vitro data only. Human hormone markers have not been formally tested.
Doping flag: Anti-doping detection methods are already in development for SLU-PP-332 and the related SLU-PP-915 (Möller, Krug, Thevis, PMID 41588687). The research community already classifies this compound as having real performance-enhancement and doping potential — worth knowing for competitive athletes operating under WADA or similar frameworks.
Regulatory status
research_only, not FDA-approved, not eligible for compounding. Anti-doping detection methods already in development (doping-potential flag). OHM grade: D / provisional (encyclopedia-only). Not in Alyve’s launch catalog of 15 SKUs.
Sources
- thepeptidelist.com directory profile; primary source for mechanism, evidence tier, and regulatory status (all site-derived citations carry per KB doctrine).
- OHM tier/safety grading (D/provisional).
- Pruski / Research Radar (Substack) reconstitution experiment; source for DMSO solubility (~75 mg/ml), water-insolubility observation, and reconstitution protocol.
- DeLauer YouTube video digest (2026-07-27); source for SNS-comparison framing, Burris lab JPET study data (12%/10×), ACS Chemical Biology foundational exercise-mimetic study, type 2A fiber shift, GLUT4/PGC-1α upregulation, exercise synergy section, no hormone suppression note.
- PMIDs cited (confirmed in prior digests): 41421047 (Billon et al. 2026, J Pharmacol Exp Ther — SLU-PP-915 exercise capacity in mice), 37717940 (Wang et al. 2023, Am J Pathol — ERR agonism and aging-kidney dysfunction), 41588687 (Möller, Krug, Thevis 2026, Rapid Commun Mass Spectrom — metabolite characterization and doping-potential flag).
- PMIDs needed (from DeLauer digest — not yet confirmed): Burris lab JPET obese-mouse study (12% weight loss / 10× fat data); Burris lab ACS Chemical Biology exercise-mimetic study (type 2A fiber shift / ERR-α dependency / PGC-1α / GLUT4).
Related: AICAR · MOTS-c · SS-31 (Elamipretide) · Retatrutide · mitochondrial-compounds-framework · The GLP-1 Pipeline (2026).
Sources & references
- thepeptidelist.com directory profile; primary source for mechanism, evidence tier, and regulatory status (all site-derived citations carry per KB doctrine).
- OHM tier/safety grading (D/provisional).
- Pruski / Research Radar (Substack) reconstitution experiment; source for DMSO solubility (~75 mg/ml), water-insolubility observation, and reconstitution protocol.
- DeLauer YouTube video digest (2026-07-27); source for SNS-comparison framing, Burris lab JPET study data (12%/10×), ACS Chemical Biology foundational exercise-mimetic study, type 2A fiber shift, GLUT4/PGC-1α upregulation, exercise synergy section, no hormone suppression note.
- PMIDs cited (confirmed in prior digests): 41421047 (Billon et al. 2026, J Pharmacol Exp Ther — SLU-PP-915 exercise capacity in mice), 37717940 (Wang et al. 2023, Am J Pathol — ERR agonism and aging-kidney dysfunction), 41588687 (Möller, Krug, Thevis 2026, Rapid Commun Mass Spectrom — metabolite characterization and doping-potential flag).
- PMIDs needed (from DeLauer digest — not yet confirmed): Burris lab JPET obese-mouse study (12% weight loss / 10× fat data); Burris lab ACS Chemical Biology exercise-mimetic study (type 2A fiber shift / ERR-α dependency / PGC-1α / GLUT4).
Related: AICAR · MOTS-c · SS-31 (Elamipretide) · Retatrutide · mitochondrial-compounds-framework · The GLP-1 Pipeline (2026).